Protocol Ledger

NCT05065190 · Phase III · COMPLETED

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

Interventional Phase III clinical trial protocol NCT05065190 sponsored by Boehringer Ingelheim in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-25 Enrollment: 81 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05065190
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)81 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05065190
Protocol FieldVerified Registry Value
NCT IdentifierNCT05065190
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment81 participants (ACTUAL)
Registered Start Date2021-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI